Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma.
Animals
Carcinoma, Hepatocellular
/ drug therapy
Databases, Genetic
Drug Resistance
Gene Expression Regulation, Neoplastic
/ drug effects
Gene Regulatory Networks
/ drug effects
Humans
Liver Neoplasms
/ drug therapy
Mice
Sorafenib
/ pharmacology
Survival Analysis
Transcription Factors
/ metabolism
Xenograft Model Antitumor Assays
Dysfunctional gene
Hepatocellular carcinoma
Molecular mechanisms
Sorafenib resistance
Transcription factors
Journal
Cancer genetics
ISSN: 2210-7762
Titre abrégé: Cancer Genet
Pays: United States
ID NLM: 101539150
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
17
10
2019
revised:
28
02
2020
accepted:
23
04
2020
pubmed:
20
6
2020
medline:
18
12
2020
entrez:
20
6
2020
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is an intractable disease because patients with HCC frequently develop sorafenib resistance after long-term chemotherapy. Although studies has demonstrated the availability of cumulative information on drug-resistant patients, little is known about the strategies and molecular mechanisms to reverse sorafenib resistance. Here, the present study identified critical mRNAs and transcription factors (TFs) associated with sorafenib resistance of HCC and evaluated the significance correlation between drug-resistant genes and TFs in comprehensive network for HCC xenografts mice. The expression profiles of mRNAs were compared between sorafenib-acquired resistant tissue and sorafenib sensitive tissue utilizing RNA-Seq data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Gene Ontology and KEGG pathway analysis were performed to investigate the biological function of significantly dysregulated mRNA. Furthermore, the Kaplan-Meier survival analyses were performed to evaluate the effect of mRNA on over survival. Subsequently, TFs were predicted using TRANSFAC and TF-mRNA regulatory networks were visualized using cytoscape software. A total of 827 mRNAs were found to be differentially expressed in sorafenib-acquired resistant tissue compared with control. Thereafter, the results of functional enrichment analysis showed the dysregulated mRNAs involved in drug-resistant signaling pathway, including MAPK, JAK-STAT, TGF-β and drug-metabolism cytochrome P450 signaling pathway. CDK1, CDKN1A and TAPBP might serve as prognostic signature of resistance of HCC to sorafenib according to the survival analysis. Furthermore, TF-mRNA networks were constructed. There were 18 TFs were predicted to regulate differentially expressed mRNAs, which play an essential role in the regulation of dysfunctional gene networks. NFKB1 was presented in the TF-mRNA networks as the node with the highest degree and MYC was predicted as prognostic TF in drug resistance of HCC CONCLUSIONS: Taken together, our findings showed that novel mRNAs and TFs, which served as critical biomarkers to predict survival and therapeutic targets of resistance to sorafenib in HCC. Furthermore, we constructed the TF-mRNA networks, which provides valuable theoretical references to further evaluate the molecular mechanisms of resistance to sorafenib in HCC.
Identifiants
pubmed: 32559715
pii: S2210-7762(20)30234-9
doi: 10.1016/j.cancergen.2020.04.076
pii:
doi:
Substances chimiques
Transcription Factors
0
Sorafenib
9ZOQ3TZI87
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
27-34Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing Interest The authors declare no competing interest.